Lisman T - Search Results

1

Consequences of abnormal hemostasis tests for clinical practice.

Lisman T, Caldwell SH, Porte RJ, Leebeek FW. Lisman T, et al. J Thromb Haemost. 2006 Sep;4(9):2062-3. doi: 10.1111/j.1538-7836.2006.02077.x. J Thromb Haemost. 2006. PMID: 16961615 Free article. No abstract available.

2

Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis.

Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Horbach DA, et al. Among authors: lisman t. Thromb Haemost. 1999 Jan;81(1):87-95. Thromb Haemost. 1999. PMID: 10348717

3

Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.

Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG. Lisman T, et al. Gastroenterology. 2001 Jul;121(1):131-9. doi: 10.1053/gast.2001.25481. Gastroenterology. 2001. PMID: 11438502

4

The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.

Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. Mosnier LO, et al. Among authors: lisman t. Thromb Haemost. 2001 Oct;86(4):1035-9. Thromb Haemost. 2001. PMID: 11686321

5

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Lisman T, et al. Hepatology. 2002 Mar;35(3):616-21. doi: 10.1053/jhep.2002.31771. Hepatology. 2002. PMID: 11870375

6

Haemostatic abnormalities in patients with liver disease.

Lisman T, Leebeek FW, de Groot PG. Lisman T, et al. J Hepatol. 2002 Aug;37(2):280-7. doi: 10.1016/s0168-8278(02)00199-x. J Hepatol. 2002. PMID: 12127437 Review. No abstract available.

7

Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis.

Meijer K, Hendriks HG, De Wolf JT, Klompmaker IJ, Lisman T, Hagenaars AA, Slooff MJ, Porte RJ, van der Meer J. Meijer K, et al. Among authors: lisman t. Blood Coagul Fibrinolysis. 2003 Feb;14(2):169-74. doi: 10.1097/01.mbc.0000046194.72384.99. Blood Coagul Fibrinolysis. 2003. PMID: 12632027 Clinical Trial.

8

Mechanism of action of recombinant factor VIIa.

Lisman T, De Groot PG. Lisman T, et al. J Thromb Haemost. 2003 Jun;1(6):1138-9. doi: 10.1046/j.1538-7836.2003.00225.x. J Thromb Haemost. 2003. PMID: 12871309 Free article. No abstract available.

9

Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.

Lisman T, de Groot PG, Lambert T, Røjkjaer R, Persson E. Lisman T, et al. J Thromb Haemost. 2003 Oct;1(10):2175-8. doi: 10.1046/j.1538-7836.2003.00444.x. J Thromb Haemost. 2003. PMID: 14521601 Free article.

10

Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.

Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK, De Groot PG. Lisman T, et al. J Thromb Haemost. 2003 Nov;1(11):2368-73. doi: 10.1046/j.1538-7836.2003.00536.x. J Thromb Haemost. 2003. PMID: 14629471 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

391 results

Search Page

Filters